Transarterial embolization of gastroduodenal peptic ulcer bleeding: a single-center study of safety and efficacy.

IF 2.1 3区医学 Q2 SURGERY

Langenbeck's Archives of Surgery Pub Date : 2025-04-02 DOI:10.1007/s00423-025-03695-8

Cihan Ozen, Muhanad Al-Hashimi, Mogens Tornby Stender, Ole Thorlacius-Ussing, Anders Christian Larsen

{"title":"Transarterial embolization of gastroduodenal peptic ulcer bleeding: a single-center study of safety and efficacy.","authors":"Cihan Ozen, Muhanad Al-Hashimi, Mogens Tornby Stender, Ole Thorlacius-Ussing, Anders Christian Larsen","doi":"10.1007/s00423-025-03695-8","DOIUrl":null,"url":null,"abstract":"Objectives: To investigate the safety and efficacy of transarterial embolization (TAE) in patients with bleeding gastroduodenal peptic ulcers with an emphasis on prophylactic TAE (pTAE).Methods: This retrospective cohort study was conducted from 1 January 2010 to 30 June 2022. The primary outcome was rebleeding rate after TAE. Secondary outcomes were frequency and severity of complications, 30-day mortality rate, and overall survival.Results: 87 patients were included. The overall rebleeding rate after TAE was 13/87 (15%). The rebleeding rate was non-significantly higher in the therapeutic TAE (tTAE) group (31%) when compared to the pTAE group (12%). Minor complications were observed in 14/87 patients (16%) and severe complications were observed in 6/87 patients (7%). The complication rate did not differ between the tTAE and pTAE groups. The 30-day overall mortality rate was 19/87 (22%). The 30-day mortality rate was non-significantly higher in the tTAE-group (31%) when compared to the pTAE group (20%). Of the 19 mortalities within 30-days, three were considered procedure-related. The overall median survival rate was 21 months (95% CI: 9.8 - 31). A non-significant higher median survival of 46.7 months (95% CI 1.2 - 74.9) was observed in the tTAE group when compared to 20.5 months (95% CI 7.1-29.1) in the pTAE group.Conclusion: TAE is safe and efficient but is associated with a high 30-day mortality rate and poor overall survival owing to a high burden of comorbidity and disease-related rather than TAE-related complications. Further studies are needed to clarify the gain and selection criteria for pTAE.","PeriodicalId":17983,"journal":{"name":"Langenbeck's Archives of Surgery","volume":"410 1","pages":"117"},"PeriodicalIF":2.1000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965190/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Langenbeck's Archives of Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00423-025-03695-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: To investigate the safety and efficacy of transarterial embolization (TAE) in patients with bleeding gastroduodenal peptic ulcers with an emphasis on prophylactic TAE (pTAE).

Methods: This retrospective cohort study was conducted from 1 January 2010 to 30 June 2022. The primary outcome was rebleeding rate after TAE. Secondary outcomes were frequency and severity of complications, 30-day mortality rate, and overall survival.

Results: 87 patients were included. The overall rebleeding rate after TAE was 13/87 (15%). The rebleeding rate was non-significantly higher in the therapeutic TAE (tTAE) group (31%) when compared to the pTAE group (12%). Minor complications were observed in 14/87 patients (16%) and severe complications were observed in 6/87 patients (7%). The complication rate did not differ between the tTAE and pTAE groups. The 30-day overall mortality rate was 19/87 (22%). The 30-day mortality rate was non-significantly higher in the tTAE-group (31%) when compared to the pTAE group (20%). Of the 19 mortalities within 30-days, three were considered procedure-related. The overall median survival rate was 21 months (95% CI: 9.8 - 31). A non-significant higher median survival of 46.7 months (95% CI 1.2 - 74.9) was observed in the tTAE group when compared to 20.5 months (95% CI 7.1-29.1) in the pTAE group.

Conclusion: TAE is safe and efficient but is associated with a high 30-day mortality rate and poor overall survival owing to a high burden of comorbidity and disease-related rather than TAE-related complications. Further studies are needed to clarify the gain and selection criteria for pTAE.

查看原文本刊更多论文

经动脉栓塞治疗胃十二指肠消化性溃疡出血：安全性和有效性的单中心研究。

目的：探讨经动脉栓塞（TAE）治疗胃十二指肠消化性溃疡出血患者的安全性和有效性，重点是预防性TAE （pTAE）。方法：本回顾性队列研究于2010年1月1日至2022年6月30日进行。主要观察指标为TAE后再出血率。次要结局是并发症的发生频率和严重程度、30天死亡率和总生存率。结果：共纳入87例患者。TAE后总再出血率为13/87（15%）。与pTAE组（12%）相比，治疗性TAE组（tTAE）的再出血率（31%）无显著性升高。轻微并发症14/87例（16%），严重并发症6/87例（7%）。并发症发生率在tae组和pTAE组之间没有差异。30天总死亡率为19/87（22%）。与pTAE组（20%）相比，ttae组（31%）的30天死亡率无显著性升高。在30天内的19例死亡中，3例被认为与手术有关。总中位生存率为21个月（95% CI: 9.8 - 31）。与pTAE组的20.5个月（95% CI 7.1-29.1）相比，tTAE组的中位生存期为46.7个月（95% CI 1.2 - 74.9），无显著性提高。结论：TAE是安全有效的，但由于并发症和疾病相关而非TAE相关并发症的高负担，TAE与较高的30天死亡率和较差的总生存率相关。需要进一步的研究来阐明pTAE的增益和选择标准。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Langenbeck's Archives of Surgery 医学-外科

CiteScore

3.30

自引率

8.70%

发文量

342

审稿时长

4-8 weeks

期刊介绍： Langenbeck''s Archives of Surgery aims to publish the best results in the field of clinical surgery and basic surgical research. The main focus is on providing the highest level of clinical research and clinically relevant basic research. The journal, published exclusively in English, will provide an international discussion forum for the controlled results of clinical surgery. The majority of published contributions will be original articles reporting on clinical data from general and visceral surgery, while endocrine surgery will also be covered. Papers on basic surgical principles from the fields of traumatology, vascular and thoracic surgery are also welcome. Evidence-based medicine is an important criterion for the acceptance of papers.